TY - JOUR
T1 - Gender-affirming treatment and mental health diagnoses in Danish transgender persons
T2 - a nationwide register-based cohort study
AU - Glintborg, Dorte
AU - Møller, Jens-Jakob Kjer
AU - Rubin, Katrine Hass
AU - Lidegaard, Øjvind
AU - T'Sjoen, Guy
AU - Larsen, Mie-Louise Julie Ørsted
AU - Hilden, Malene
AU - Andersen, Marianne Skovsager
N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For permissions, please e-mail: [email protected].
PY - 2023/9/1
Y1 - 2023/9/1
N2 - IMPORTANCE: Gender affirming treatment aims to improve mental health.OBJECTIVE: To investigate longitudinal mental health outcomes in Danish transgender persons.DESIGN: National register-based cohort study in Danish transgender persons with diagnosis code of "gender identity disorder" during the period 2000-2021.PARTICIPANTS: Five age-matched controls of the same sex at birth and five age-matched controls of the other sex at birth were included for each transgender person.MAIN OUTCOMES: Diagnosis codes of mental and behavioral disorders and/or prescription of psychopharmacological agents until June 2022.RESULTS: The cohort included 3812 transgender persons with median age (interquartile range) 19 (15; 24) years for persons assigned female at birth (AFAB, N = 1993) and 23 (19; 33) years for persons assigned male at birth (AMAB, N = 1819) and 38 120 controls. Follow up duration was up to 10 years with mean (standard deviation) 4.5 (4.3) years. In transgender persons AFAB compared to control women, the odds ratio (OR) (95% confidence interval) for mental and behavioral disorders was 6.7 (5.5; 8.1) before the index date, 9.9 (8.4; 11.7) at 1 year, 5.8 (4.4; 7.7) at 5 years, and 3.4 (2.1; 7.5) at 8 years follow up. In transgender persons AMAB compared to control men, corresponding ORs were 5.0 (4.0; 6.4), 11.3 (9.3; 13.7), 4.8 (3.5; 6.5), and 6.6 (4.2; 10.3) at 8 years follow up (all P < .001).CONCLUSION: The OR for mental health disorders was higher in transgender persons compared to controls and remained elevated throughout follow up, especially in transgender persons AMAB.
AB - IMPORTANCE: Gender affirming treatment aims to improve mental health.OBJECTIVE: To investigate longitudinal mental health outcomes in Danish transgender persons.DESIGN: National register-based cohort study in Danish transgender persons with diagnosis code of "gender identity disorder" during the period 2000-2021.PARTICIPANTS: Five age-matched controls of the same sex at birth and five age-matched controls of the other sex at birth were included for each transgender person.MAIN OUTCOMES: Diagnosis codes of mental and behavioral disorders and/or prescription of psychopharmacological agents until June 2022.RESULTS: The cohort included 3812 transgender persons with median age (interquartile range) 19 (15; 24) years for persons assigned female at birth (AFAB, N = 1993) and 23 (19; 33) years for persons assigned male at birth (AMAB, N = 1819) and 38 120 controls. Follow up duration was up to 10 years with mean (standard deviation) 4.5 (4.3) years. In transgender persons AFAB compared to control women, the odds ratio (OR) (95% confidence interval) for mental and behavioral disorders was 6.7 (5.5; 8.1) before the index date, 9.9 (8.4; 11.7) at 1 year, 5.8 (4.4; 7.7) at 5 years, and 3.4 (2.1; 7.5) at 8 years follow up. In transgender persons AMAB compared to control men, corresponding ORs were 5.0 (4.0; 6.4), 11.3 (9.3; 13.7), 4.8 (3.5; 6.5), and 6.6 (4.2; 10.3) at 8 years follow up (all P < .001).CONCLUSION: The OR for mental health disorders was higher in transgender persons compared to controls and remained elevated throughout follow up, especially in transgender persons AMAB.
KW - depression
KW - gender-affirming hormone
KW - gender-affirming surgery
KW - medicine prescription
KW - mental health
KW - register based
KW - suicide
KW - transgender
UR - http://www.scopus.com/inward/record.url?scp=85181033671&partnerID=8YFLogxK
U2 - 10.1093/ejendo/lvad119
DO - 10.1093/ejendo/lvad119
M3 - Journal article
C2 - 37672620
SN - 0804-4643
VL - 189
SP - 336
EP - 345
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
IS - 3
ER -